IASO Bio and Innovent Announce the NMPA Approval of the New

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refrac

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refrac

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Nanjing , Jiangsu , China , Huazhong , Hubei , Shanghai , United States , Hong Kong , Tongji , Sichuan , Rhui Zhou , Guangdong , American , Chinese , Equecabtagene Autoleucel , Lugui Qiu , Eli Lilly , Adimab Incyte , Chunrui Li , Jinghua Zhang , Innovent Biologics , Innovent Biologics Inc , Tongji Medical College , Chinese Academy Of Medical Science Hematology Hospital , China National Medical Products Administration , Md Anderson Cancer Center , Huazhong University Of Science Technology , New Drug Application , American Society , Clinical Oncology , Abstract Number , Progression Free Survival , Chinese Academy , Medical Science Hematology Hospital , Tongji Hospital , Huazhong University , Chief Executive Officer , Senior Vice President , Multiple Myeloma , National Medical Products Administration , Breakthrough Therapy Designation , Orphan Drug Designation , Regenerative Medicine Advanced Therapy , Fast Track , Neuromyelitis Optica Spectrum Disorder , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center ,